Ongoing Clinical Trial Studies
Active
Renal Medicine Associates collaborates with multiple institutions to explore innovative therapeutic options for selected patients, prioritizing excellence in care. With a diverse portfolio of past and present clinical trials, RMA has a proven track record of success in advancing kidney health. We are committed to enhancing access to novel treatment options in New Mexico, empowering patients with a broader range of choices that align with the latest advancements in medicine.
Glomerular & Genetic Disease
Sponsor: Alpine Immune Science
Protocol: AIS-D08
A phase 3, randomized, double-blind, placebo-controlled study of povetacicept in adults with IgAN (Rainier)
Glomerular and Genetic Diseases
Sponsor: Travere Therapeutics
Protocol: TVTX-RE021-204
A multicentered, single-group phase 2, exploratory, open-label study to investigate safety and effect of sparsentan in combination with sodium glucose cotransporter-2 (SGLT2) inhibition in the treatment of adult participants with IDA nephropathy (IGAN)
glomerular and genetic diseases
Sponsor: Vera Therapeutics
Protocol: VT-001-0050
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN).
glomerular and genetic diseases
Sponsor: Vertex Pharmaceuticals Incorporated
Protocol: VX21-147-301
A Phase 2/3 Adaptive, Double-blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of VX- 147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease Vertex Study Number: VX21-147-301 IND Number: 141671.
glomerular and genetic diseases
Sponsor: Vertex Pharmaceuticals Incorporated
Protocol: VX19-NEN-801
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.
infectious diseases
Sponsor: Shionogi
Protocol: ACTIV-2D/A5407
A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S- 217622 compared with placebo in non-hospitalized participants with COVID-19.
infectious diseases
Sponsor: AstraZeneca AB
Protocol: D7000C00001 SuperNova
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
Cardiometabolic Medicine
Sponsor: Novo Nordisk
Protocol: NN9838-4942
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease.
Cardiometabolic Medicine
Sponsor: Alnylam Pharmaceuticals
Protocol: ALN-AGT01-007
Description: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications
Closed for Enrollment
Cardiometabolic Medicine
Novo Nordisk
Protocol: NN9535-4321
Description: The FLOW study evaluated the effectiveness of semaglutide in delaying kidney disease progression and reducing cardiovascular-related deaths in Type 2 Diabetes patients with chronic kidney disease, finding a 24% lower risk compared to placebo
Chronic Kidney Disease
Sponsor: AstraZeneca AB
Protocol: D9488C00001
Description: A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with CKD and Hyperkalemia or at Risk of Hyperkalemia
Closed for Enrollment
End - stage kidney disease
Sponsor: Merck Sharp & Dohme Corporation
Protocol: 007-00
Description: A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
Contact Research Team Member